论文部分内容阅读
目的比较急性心肌梗死患者有或无糖尿病早期静脉溶栓治疗的有效性和安全性,以及溶栓后4周内再发心肌缺血事件及心功能状况。方法65例急性心肌梗死患者给予相同的溶栓剂治疗。结果有糖尿病组和无糖尿病组的血管再通率分别为55.8%和73.2%(P<0.05),出血等不良反应发生率为5.2%和3.6%(P<0.05);死亡率为20.6%和5.8%(P<0.05);溶栓后4周内再发心肌缺血事件的发生率有糖尿病组和无糖尿病组分别为15.2%和3.6%(P<0.05);左室心肌射血分数(LVEF)值分别为46±8和60±11(P<0.05)。结论急性心肌梗死患者合并糖尿病溶栓治疗血管再通率明显低于无糖尿病患者,且近期预后亦差。
Objective To compare the efficacy and safety of early intravenous thrombolytic therapy in patients with or without acute myocardial infarction and the occurrence of myocardial ischemia and cardiac function within 4 weeks after thrombolysis. Methods 65 patients with acute myocardial infarction were given the same thrombolytic therapy. Results The rates of revascularization in diabetic group and non-diabetic group were 55.8% and 73.2% (P <0.05), and the incidence of adverse reactions such as bleeding were 5.2% and 3.6% (P <0.05) respectively; the mortality rate was 20.6% and 5.8% (P <0.05). The incidence of myocardial ischemic reperfusion within 4 weeks after thrombolysis was 15.2% and 3.6% respectively in diabetic group and non-diabetic group (P <0.05) LVEF) were 46 ± 8 and 60 ± 11, respectively (P <0.05). Conclusion The recanalization rate of thrombolytic therapy in patients with acute myocardial infarction is significantly lower than that of non-diabetic patients, and the prognosis is also poor recently.